Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Shridar Ganesan
Rbhs Cancer Institute of New Jersey, Department: None
Should you be removed from our database? Contact us at [email protected]. Read more below.
IBRIS Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Ganesan holds equity interest in, is co-founder of and consultant for a start-up company (IBRIS Inc.) that is developing technology for quick and economical analysis of tissue from breast cancer biopsies, to predict how aggressive a common form of breast cancer is likely to be. The company does not have any value at this time. Dr. Ganesan and IBRIS Inc also hold patents on methods for image analysis of histology of ER+ breast cancers for prognosis.The Rutgers Biomedical and Health Sciences (RBHS) Investigator Conflict of Interest Committee reviewed the above disclosure and determined that the significant financial interest may or may not serve as secondary interests in this project. This is primarily due to the fact that no specific protocols or drugs are named in the application. Indeed it seems to be the intent of the project to devise novel therapies. While acceptable, it also suggests that this researcher may introduce bias into the protocols that favor the companies with which they are associated. Hence the clear perception of a COI exists on the part of this investigator in this case.
Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics
RELEVANCE: This application will merge two strong prior Phase I (UOl) sites to create the Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics (WIN-Alliance). This group, as a synergistic, multidisciplinary and multi-institutional model, will develop and evaluate innovative, early phase experimental therapeutic clinical trials to improve clinical outcomes.
Filed on May 12, 2014.
Tell us what you know about Shridar Ganesan's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Shridar Ganesan”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Shridar Ganesan | Rbhs Cancer Institute of New Jersey | Conflict of Interest | Ibris Inc | Value cannot be readily determined |
| Shridar Ganesan | Case Western Reserve University | Conflict of Interest | Inspirata, Inc. | Value cannot be readily determined |
| Shridar Ganesan | Rbhs Cancer Institute of New Jersey | Conflict of Interest | Inspirata Inc | $40,000 - $59,999 |
| Shridar Ganesan | Rbhs Cancer Institute of New Jersey | Conflict of Interest | Rutgers, The State University of New Jersey | Value cannot be readily determined |
| Shridar Ganesan | Rutgers, the State Univ of n.j. | Conflict of Interest | Rutgers, The State University of New Jersey | Value cannot be readily determined |
| Shridar Ganesan | Rutgers, the State Univ of n.j. | Conflict of Interest | Ibris Inc | Value cannot be readily determined |
| Shridar Ganesan | Case Western Reserve University | Conflict of Interest | Inspirata, Inc. | $60,000 - $79,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.